ArticleJournal of health, population, and nutrition2025
Global, regional, and national burden of uterine cancer among women aged 50 years and older from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.
Article in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Identification of prognostic risk factors and construction of nomograms for elderly patients with stage III-IV endometrioid endometrial carcinoma: a study based on the SEER database.Translational cancer research · 2026Article
- Personalizing Liposomal Paclitaxel in Platinum-Based Combination Therapy for Gynecologic Cancers: Defining a Therapeutic Window Based on TcEuropean journal of drug metabolism and pharmacokinetics · 2026Article
- Endometriosis and Endometrial Cancer-Association Between Biological Mechanisms and Its Clinical Implications.Journal of clinical medicine · 2026Review
- Quantitative Texture Analysis of Cervical Cytology Identifies Endometrial Lesions in Atypical Glandular Cells on Liquid-Based Cytology: A Pilot Study.Diagnostics (Basel, Switzerland) · 2026Article
- Label-free quantitative urinary proteomics for non-invasive biomarker discovery in endometrial cancer.Frontiers in medicine · 2026Article
- Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management.Cancers · 2025Review
- The rising burden of female cancer in Ethiopia (2000-2021) and projections to 2040: Insights from the global burden of disease study.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUterine cancer poses a growing global health threat, with rising incidence among women aged ≥ 50 years. This study aimed to evaluate its disease burden across regions and nations.
methodsUsing Global Burden of Disease 2021 data, we analyzed the incidence, mortality, disability-adjusted life years (DALYs), and trends via estimated annual percentage change (EAPC), decomposition, inequality analyses, and Bayesian Age-Period-Cohort modeling for 2022-2040 projections.
resultsIn 2021, global uterine cancer cases among women ≥ 50 years reached 414,754 (95% UI: 370,388-453,502), causing 90,509 deaths (95% UI: 78,633-101,441) and 2,189,261 DALYs (95% UI: 1,920,396-2,446,737). Age-standardized incidence rate (ASIR) rose (EAPC = 0.56, 1990-2021), while mortality and DALYs declined. High-income North America had the highest ASIR (128/100,000), with the United States, China and Russia leading new cases. High Socio-demographic index (SDI) regions exhibited widening disparities, evidenced by a 21% increase in the slope index of inequality (SII) for incidence (47 in 1990 to 57 in 2021) and concentration indices (CI) rising from 0.33 (95% CI: 0.28, 0.37) in 1990 to 0.35 (95% CI: 0.29, 0.4) in 2021. Population growth drove 132.55% of DALY changes, outweighing epidemiological (-32.95%) and aging (0.4%) factors. Projections suggest declining ASIR, the age-standardized mortality rate (ASMR), and DALY rates by 2040, yet absolute cases will rise to 617,571 new cases, 131,961 deaths, and 2,851,768 DALYs.
conclusionsDespite declining mortality and DALY rates, uterine cancer incidence continued to increase globally, driven by population growth. High-income regions faced disproportionate burdens, with persistent health inequities. Projected absolute case growth demands urgent prioritization of equity-oriented screening, prevention, and resource allocation. Governments must integrate targeted interventions with global aging policies to address this dual burden of epidemiological transition and health inequity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.